Geron Corporation (GERN)
收市後：
| 前收市價 | 3.5800 |
| 開市 | 3.6300 |
| 買盤 | 3.6800 x 300 |
| 賣出價 | 3.7100 x 5600 |
| 今日波幅 | 3.6300 - 3.8000 |
| 52 週波幅 | 1.6400 - 4.0500 |
| 成交量 | |
| 平均成交量 | 12,617,530 |
| 市值 | 2.164B |
| Beta 值 (5 年，每月) | 0.61 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.3200 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.08 |
ZacksBiotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
ZacksGeron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
BenzingaGeron Stock Is Soaring After Hours: What's Going On?
Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia. What Happened: After the market close on Thursday, Geron announced that ODAC voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusio
